A Phase 3 interventional study of Upadacitinib and Placebo for upadacitinib in Atopic Dermatitis, sponsored by AbbVie. Completed at 43 sites in Japan. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-01.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.
Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one is the 9th largest by enrollment, is one of 4 that started in 2018, is one of 12 in phase 3, and was the 6th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
RenJi Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 272 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 272 across the 17 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
34 studies in Dermatitis, Atopic by AbbVie: 3 open now, 12 under way, 4 of them phase 3. Of 19 finished, 8 (42%) have results posted.
Among the 34 studies in Dermatitis, Atopic by AbbVie, this one is the 11th largest by enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2018, is one of 12 in phase 3, and was the 6th registered.
AbbVie’s Dermatitis, Atopic studies by the year they started, since 2016.
3 of the studies testing upadacitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT06701331Phase 3AbbVieSafety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis | 2027-01 |
| NCT07678645RenJi HospitalThe Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies testing upadacitinib in Dermatitis, Atopic, from their registry updates:
Among AbbVie’s 34 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the safety of upadacitinib combined with topical corticosteroids (TCS) in adolescent and adult participants in Japan with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Upadacitinib Dose A is administered once daily along with Topical Corticosteroids (TCS).
Drug: Upadacitinib · Drug: Topical Corticosteroids (TCS)
Upadacitinib Dose B is administered once daily along with Topical Corticosteroids (TCS).
Drug: Upadacitinib · Drug: Topical Corticosteroids (TCS)
Placebo administered once daily and TCS followed by Upadacitinib Dose A once daily along with TCS.
Drug: Upadacitinib · Drug: Placebo for upadacitinib · Drug: Topical Corticosteroids (TCS)
Placebo administered once daily and TCS followed by Upadacitinib Dose B once daily along with TCS.
Drug: Upadacitinib · Drug: Placebo for upadacitinib · Drug: Topical Corticosteroids (TCS)
Upadacitinib is administered orally.
Also known as: ABT-494
Placebo is administered orally.
It is administered concomitantly with upadacitinib or placebo.
Number of participants experiencing adverse events
Adverse events are defined as those that began or worsened in severity after the first dose of study drug but within 30 days after the last dose of study drug.
Time frame: Up to 141 Weeks
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Oct 2018 to primary completion in Aug 2022, 45 months.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 45 months is above that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Upadacitinib · Topical Corticosteroid